Nivalis shareholders approve merger with Alpine Immune Sciences

BOULDER  — Shareholders of Nivalis Therapeutics Inc. (Nasdaq: NVLS) have approved its merger with Alpine Immune Sciences Inc.

At a special meeting of stockholders July 19, the merger was approved, as was the issuance of Nivalis’ common stock to Alpine shareholders.

The merger was announced in April, with Nivalis shareholders owning about 26 percent of the combined company and Seattle-based Alpine shareholders owning 74 percent.

Navalis shareholders also approved a reverse stock split of Nivalis’ common stock, which will offer one new…